Rapid effects of aldosterone on clonal human vascular smooth muscle cells

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 2, 2007, Pages

  Gros, Robert ^a   Ding, Qingming ^a   Armstrong, Souzan ^a   O'Neil, Caroline ^a   Pickering, J Geoffrey ^a,b   Feldman, Ross D ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Contraction; Nongenomic; Steroid hormones

Indexed keywords

ALDOSTERONE; EPLERENONE; ESTRADIOL; ESTROGEN; GLUCOCORTICOID; HYDROCORTISONE; MYOSIN LIGHT CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; SPIRONOLACTONE; STEROID; VASOCONSTRICTOR AGENT;

ARTICLE; CELL CLONE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; MUSCLE CONTRACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ALDOSTERONE; AORTA, THORACIC; CELL LINE; CLONE CELLS; ESTRADIOL; HUMANS; HYDROCORTISONE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN LIGHT CHAINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPIRONOLACTONE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 33847023036     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00407.2006     Document Type: Article

References (41)

1. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, Takeuchi K, Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 2255-2263, 2003.
2. Baxter JD, Funder JW, Apriletti JW, Webb P. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. Mol Cell Endocrinol 217: 151-165, 2004.
3. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364, 1990.
4. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241, 2005.
5. Budzyn K, Marley PD, Sobey CG. Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. J Pharmacol Exp Ther 313: 1248-1253, 2005.
6. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45: 773-779, 2005.
7. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71: 17A-20A, 1993.
8. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19: 1371-1376, 1998.
9. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-556, 2000.
10. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103: 425-431, 2002.
11. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, Myoishi M, Okuda H, Ogai A, Okada K, Tsukamoto O, Koyama H, Hori M, Kitakaze M. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 46: 113-117, 2005.
12. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 26: 313-321, 2005.
13. Gaeggeler HP, Gonzalez-Rodriguez E, Jaeger NF, Loffing-Cueni D, Norregaard R, Loffing J, Horisberger JD, Rossier BC. Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J Am Soc Nephrol 16: 878-891, 2005.
14. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19: 1697-1710, 2005.
15. Haseroth K, Gerdes D, Berger S, Feuring M, Gunther A, Herbst C, Christ M, Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun 266: 257-261, 1999.
16. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316-24320, 1994.
17. Jiang G, Cobbs S, Klein JD, O'Neill WC. Aldosterone regulates the Na-K-2Cl cotransporter in vascular smooth muscle. Hypertension 41: 1131-1135, 2003.
18. Li S, Fan YS, Chow LH, Van Den Diepstraten C, van Der Veer E, Sims SM, Pickering JG. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ Res 89: 517-525, 2001.
19. Li S, Sims S, Jiao Y, Chow LH, Pickering JG. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ Res 85: 338-348, 1999.
20. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400-2406, 2003.
21. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146: 973-980, 2005.
22. 2+ during agonist activation of permeabilized arteries. Am J Physiol Cell Physiol 263: C540-C544, 1992.
23. + secretion by turtle urinary bladder. J Clin Invest 61: 1666-1670, 1978.
24. Persechini A, Kamm KE, Stull JT. Different phosphorylated forms of myosin in contracting tracheal smooth muscle. J Biol Chem 261: 6293-6299, 1986.
25. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
27. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166: 345-349, 2003.
28. Sakauye C, Feldman D. Agonist and antimineralocorticoid activities of spirolactones. Am J Physiol 231: 93-97, 1976.
29. Schmidt BM, Georgens AC, Martin N, Tillmann HC, Feuring M, Christ M, Wehling M. Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab 86: 761-767, 2001.
30. Schmidt BM, Montealegre A, Janson CP, Martin N, Stein-Kemmesies C, Scherhag A, Feuring M, Christ M, Wehling M. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab 84: 3528-3533, 1999.
31. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42: 156-160, 2003.
32. Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 144: 1164-1174, 2003.
33. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein complex formation involving ERα and Src. Trends Endocrinol Metab 16: 347-353, 2005.
34. Suzuki T, Nakamura Y, Moriya T, Sasano H. Effects of steroid hormones on vascular functions. Microsc Res Tech 60: 76-84, 2003.
35. + transport by aldosterone: signaling convergence and cross talk between the PI3-K and MAPK1/2 cascades. Am J Physiol Renal Physiol 286: F1232-F1238, 2004.
36. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, Sorensen GL, Skott O. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 1258-1266, 2003.
37. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
38. 2+ in vascular smooth muscle cells. Circ Res 76: 973-979, 1995.
39. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 83: 3517-3522, 1998.
40. White RE, Han G, Dimitropoulou C, Zhu S, Miyake K, Fulton D, Dave S, Barman SA. Estrogen-induced contraction of coronary arteries is mediated by superoxide generated in vascular smooth muscle. Am J Physiol Heart Circ Physiol 289: H1468-H1475, 2005.
41. 1-Adrenoceptor- mediated phosphorylation of MYPT-1 and CPI-17 in the uterine artery: role of ERK/PKC. Am J Physiol Heart Circ Physiol 288: H2828-H2835, 2005.